COVID-19 Regulatory Special-Weekly Newsletter
Perhaps anti-TFPI no longer a feasible strategy for Hemophilia-Novo Nordisk suspended three TFPI trials
The discovery and characterization of the anticoagulant protein factor pathway inhibitor (TFPI) has led to the realization that inhibiting TFPI activity could restore functional hemostasis through the extrinsic pathway of blood clotting in a way […]